Teva Appoints John Nason President, TAPI and Biologics Operations
Teva announced the appointment of John Nason to President, Teva Active Pharmaceutical Ingredients (TAPI), a role in which he leads the company’s vertically integrated business unit responsible for the development, manufacture, marketing and sales of bulk API for both third-party manufacturers and for Teva.
Mr. Nason also assumes responsibility for the company’s biologics operations, which play an important role in the company’s long-term strategy. He will be based at Teva’s global headquarters in Petach Tikva, Israel, and reports directly to Carlo de Notaristefani, Executive Vice President, Teva Global Operations.
“John’s deep technical expertise and strong track record distinguish him as a global leader who is exceptionally qualified for this pivotal role,” said de Notaristefani. “I am confident in John’s ability to strengthen and grow these vital business assets for Teva and fully realize their potential to help patients and deliver for our customers around the world.”
Mr. Nason joined Teva in 2015 as Senior Vice President of European Technical Operations and worked closely with the company’s commercial and R&D organizations to meet customer and patient needs while closely managing the competitiveness of the product portfolio. In that position, Mr. Nason was an active member of the operations leadership team responsible for setting strategy and managing Teva’s global operations, a role he will retain as President of TAPI and Teva’s biologics operations.
Prior to joining Teva, John served in a variety of senior leadership roles at Bristol-Myers Squibb (BMS) where, over a period of 12 years, he led their global API organization and third-party operations. Prior to that, John worked at Novartis where he led bulk API manufacturing operations in Ireland and, earlier in his career, John held technical transfer, engineering and project management roles at Sandoz in the U.S. on the design of a greenfield API site.
As a native of Ireland, John holds a Bachelor of Science degree in Chemistry from University College Cork, and a Master of Business Administration from the University of Limerick.
With the largest portfolio of API molecules in the industry, TAPI is the leading worldwide supplier of APIs with nearly 1,100 customers in more than 100 countries, including 80 percent of the top 50 global pharmaceutical companies. We were established in Israel in 1935 and today maintain a strong global presence with more than 5,000 colleagues at 24 facilities in 13 countries in R&D, regulatory, manufacturing, quality and commercial operations. We partner with our customers through every step of the API journey, from supplier selection and development to commercialization, and offer a wide range of technologies, deep technical and regulatory expertise, and high standards of quality and compliance.